Physician profile
Robert Brian Deem
NPI 1619972387
$4,323.62
in general payments reported to CMS, 2019-2025
29 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $512 · 2021: $681 · 2022: $710 · 2023: $614 · 2024: $579 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,550 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,550.26 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $703.11 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $631.05 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $485.45 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $339.48 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $331.99 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $310.03 | 2019-2024 | Verquvo, Belsomra, Januvia |
| Janssen Pharmaceuticals, INC | $217.44 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $182.39 | 2019-2020 | |
| Sanofi Pasteur INC. | $168.95 | 2019-2023 | |
| Glaxosmithkline, LLC. | $131.39 | 2019-2025 | Arexvy, Trelegy Ellipta, Bexsero |
| Kowa Pharmaceuticals America, INC. | $108.07 | 2019-2024 | Zoryve |
| Amgen INC. | $107.30 | 2021-2024 | Repatha, Otezla, Prolia |
| Exact Sciences Corporation | $98.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $96.31 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $67.31 | 2019-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $52.28 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $36.77 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.11 | 2020-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $31.65 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $23.41 | 2024 | Gemtesa |
| Dynavax Technologies Corporation | $23.36 | 2020 | |
| Scilex Pharmaceuticals INC. | $23.23 | 2025 | |
| Smith+Nephew, INC. | $21.40 | 2023 | Collagenase Santyl |
| Eisai INC. | $20.20 | 2021 | |
| Dexcom, INC. | $17.25 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $17.06 | 2022 | |
| Amneal Pharmaceuticals LLC | $16.86 | 2023 | Lyvispah |
| Astellas Pharma US INC | $15.80 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Deem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.